Predictors and Trends of MDR/RR-TB in Shenzhen China: A Retrospective 2012–2020 Period Analysis

References

• Lange C, Dheda K, Chesov D, et al. Management of drug-resistant tuberculosis. Lancet. 2019;394(10202):953–966. doi:10.1016/S0140-6736(19)31882-331526739
   PubMed Web of Science ®Google Scholar
• Millard J, Ugarte-Gil C, Moore DA. Multidrug resistant tuberculosis. BMJ. 2015;350:h882. doi:10.1136/bmj.h88225721508
   PubMed Web of Science ®Google Scholar
• World Health Organization. Guidance for the Surveillance of Drug Resistance in Tuberculosis. 6th ed. Geneva: World Health Organization; 2020.
   Google Scholar
• World Health Organization. Global tuberculosis report 2020. Geneva: World Health Organization; 2020.
   Google Scholar
• Shen X, DeRiemer K, Yuan ZA, et al. Drug-resistant tuberculosis in Shanghai, China, 2000–2006: prevalence, trends and risk factors. Int J Tuberc Lung Dis. 2009;13(2):253–259.19146756
   PubMed Web of Science ®Google Scholar
• Shao Y, Yang D, Xu W, et al. Epidemiology of anti-tuberculosis drug resistance in a Chinese population: current situation and challenges ahead. BMC Public Health. 2011;11(1):110. doi:10.1186/1471-2458-11-11021324205
   PubMed Web of Science ®Google Scholar
• Wu B, Yu Y, Du C, Liu Y, Hu D. Epidemiology of drug-resistant tuberculosis in Chongqing, China: a retrospective observational study from 2010 to 2017. PLoS One. 2019;14(12):e0216018. doi:10.1371/journal.pone.021601831821321
   PubMed Web of Science ®Google Scholar
• Shenzhen Statistics Bureau, NBS Survey Office in Shenzhen. Shenzhen Statistical Yearbook 2017. Beijing: China Statistics Press; 2017.
   Google Scholar
• Wu AF, Lu DL, Guang HY, et al. Analysis of epidemiological characteristics of pulmonary tuberculosis in Shenzhen from 2007 to 2016. J Trop Med. 2018;18(1):86–89. Chinese.
   Google Scholar
• Che XL, Wu QF, Li MZ, Guan HY, Tan WG. Detection and treatment of multidrug-resistant tuberculosis in migrating population in Shenzhen, 2012–2016. Chin J Trop Med. 2018;18(6):553–554. Chinese.
   Google Scholar
• Long Q, Qu Y, Lucas H. Drug-resistant tuberculosis control in China: progress and challenges. Infect Dis Poverty. 2016;5(1):9. doi:10.1186/s40249-016-0103-326822738
   PubMed Web of Science ®Google Scholar
• Zhu L, Yang YZ, Guan HY, et al. Trends in drug-resistant tuberculosis after the implementation of the DOTS strategy in Shenzhen, China, 2000–2013. Int J Tuberc Lung Dis. 2017;21(7):759–765. doi:10.5588/ijtld.16.075928633700
   PubMed Web of Science ®Google Scholar
• Tang WG, Guan HY, Wu QF, et al. The implement effects and innovative strategies for tuberculosis controlling among migrants. Elec J Emerg Infect Dis. 2020;5(3):145–149. Chinese.
   Google Scholar
• Jiang Q, Liu Q, Ji L, et al. Citywide transmission of multidrug-resistant tuberculosis under China’s rapid urbanization: a retrospective population-based genomic spatial epidemiological study. Clin Infect Dis. 2020;71(1):142–151. doi:10.1093/cid/ciz79031504306
   PubMed Web of Science ®Google Scholar
• Chinese Antituberculosis Association. China drug-resistant tuberculosis chemotherapy guidelines (2015). Chin J Antituberc. 2015;37(5):421–469. Chinese.
   Google Scholar
• Ding XY, Mao WH, Lu W, et al. Impact of multiple policy interventions on the screening and diagnosis of drug-resistant tuberculosis patients: a cascade analysis on six prefectures in China. Infect Dis Poverty. 2021;10(1):8. doi:10.1186/s40249-021-00793-933468247
   PubMed Web of Science ®Google Scholar
• Huang F, van den Hof S, Qu Y, et al. Added value of comprehensive program to provide universal access to care for sputum smear-negative drug-resistant tuberculosis, China. Emerg Infect Dis. 2019;25(7):1289–1296. doi:10.3201/eid2507.18141731211666
   PubMed Web of Science ®Google Scholar
• Wang L, Li R, Xu C, et al. The global fund in China: multidrug-resistant tuberculosis nationwide programmatic scale-up and challenges to transition to full country ownership. PLoS One. 2017;12(6):e0177536. doi:10.1371/journal.pone.017753628628669
   PubMed Web of Science ®Google Scholar
• Benatar SR, Upshur R. Tuberculosis and poverty: what could (and should) be done? Int J Tuberc Lung Dis. 2010;14(10):1215–1221.20843410
   PubMed Web of Science ®Google Scholar
• Zhang P, Xu G, Song Y, Tan J, Chen T, Deng G. Challenges faced by multidrug-resistant tuberculosis patients in three financially affluent Chinese cities. Risk Manag Health Policy. 2020;13:2387–2394. doi:10.2147/RMHP.S275400
   Web of Science ®Google Scholar
• Long Q, Jiang WX, Zhang H, et al. Multi-source financing for tuberculosis treatment in China: key issues and challenges. Infect Dis Poverty. 2021;10(1):17. doi:10.1186/s40249-021-00809-433750460
   PubMed Web of Science ®Google Scholar
• Xionling C, Qingfang W, Liming Z, et al. The epidemiological characteristics and treatment outcome of multi-drug resistant tuberculosis among migrating individuals in Shenzhen. Chin Prev Med. 2018;19(9):647–650.
   Google Scholar
• Li R, Ruan Y, Sun Q, et al. Effect of a comprehensive programme to provide universal access to care for sputum-smear-positive multidrug-resistant tuberculosis in China: a before-and-after study. Lancet Glob Health. 2015;3(4):e217–e228. doi:10.1016/S2214-109X(15)70021-525794675
   PubMed Web of Science ®Google Scholar
• Pradipta IS, Forsman LD, Bruchfeld J, Hak E, Alffenaar JW. Risk factors of multidrug-resistant tuberculosis: a global systematic review and meta-analysis. J Infect. 2018;77(6):469–478. doi:10.1016/j.jinf.2018.10.00430339803
   PubMed Web of Science ®Google Scholar
• Faustini AHA, Perucci CA. Risk factors for multidrug resistant tuberculosis in Europe: a systematic review. Thorax. 2006;61(2):158–163. doi:10.1136/thx.2005.04596316254056
   PubMed Web of Science ®Google Scholar
• Eshetie S, Gizachew M, Dagnew M, et al. Multidrug resistant tuberculosis in Ethiopian settings and its association with previous history of anti-tuberculosis treatment: a systematic review and meta-analysis. BMC Infect Dis. 2017;17(1):219. doi:10.1186/s12879-017-2323-y28320336
   PubMed Web of Science ®Google Scholar
• Ambaye GY, Tsegaye GW. Factors associated with multi-drug resistant tuberculosis among TB patients in selected treatment centers of Amhara Region: a case-control study. Ethiop J Health Sci. 2021;31(1):25–34.34158749
   PubMed Web of Science ®Google Scholar
• World Health Organization. Xpert MTB/RIF Implementation Manual: Technical and Operational ‘How-To’; Practical Considerations. Geneva: World Health Organization; 2014.
   Google Scholar
• Liu Z, Dong H, Wu B, et al. Is rifampin resistance a reliable predictive marker of multidrug-resistant tuberculosis in China: a meta-analysis of findings. J Infect. 2019;79(4):349–356. doi:10.1016/j.jinf.2019.08.00431400354
   PubMed Web of Science ®Google Scholar
• Smith SE, Kurbatova EV, Cavanaugh JS, Cegielski JP. Global isoniazid resistance patterns in rifampin-resistant and rifampin-susceptible tuberculosis. Int J Tuberc Lung Dis. 2012;16(2):203–205. doi:10.5588/ijtld.11.044522136739
   PubMed Web of Science ®Google Scholar
• McQuaid CF, Vassall A, Cohen T, Fiekert K, White RG. The impact of COVID-19 on TB: a review of the data. Int J Tuberc Lung Dis. 2021;25(6):436–446. doi:10.5588/ijtld.21.014834049605
   PubMed Web of Science ®Google Scholar